CARTER BRUCE L A
Known title: DirectorCIK: 0001225503
Associated companies
Transaction History
| ENTA | ▲ Buy | Option Exercise | 6,000 | $153K | 3/21/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 307 | $21K | 3/21/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,676 | $178K | 3/21/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,210 | $152K | 3/21/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 807 | $56K | 3/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.